Seres Therapeutics Stock News

The post I prefer Pfizers stock over Novavax appeared on BitcoinEthereumNews.com . Seres Therapeutics: Youre a younger person and youre new and I think you can buy it. For an older person, its too speculative because the company is not making any

The stock price of Seres Therapeutics, a small late stage clinical biotechnology company with a market cap of around $1 billion, is up a whopping 77% in a month, while it is up 17% over the last week.

The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.

The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.

The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.

The stock price of Seres Therapeutics Inc (NASDAQ: MCRB) increased by over 20% during intraday trading today. This is why it happened.

Wall Street brokerages expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to report earnings per share of ($0.53) for the current quarter, according to Zacks. Four analysts have issued estimates for Seres Therapeutics earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.62). Seres Therapeutics reported earnings per share of []

Brokerages forecast that Seres Therapeutics, Inc. (NASDAQ:MCRB) will post $6.41 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Seres Therapeutics earnings, with estimates ranging from $5.00 million to $9.64 million. Seres Therapeutics posted sales of $17.56 million during the same quarter last year, which []

Wall Street brokerages expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to post $6.41 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Seres Therapeutics earnings, with estimates ranging from $5.00 million to $9.64 million. Seres Therapeutics posted sales of $17.56 million in the same quarter last year, which []

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will take place November 29 December 2, 2021. The fireside chat will be available for on-demand viewing on the Seres website. About Seres Therapeutics Seres Ther

The stock price of Seres Therapeutics Inc (NASDAQ: MCRB) slightly increased pre-market today. This is why it happened.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres

The trading price of Seres Therapeutics Inc. (NASDAQ:MCRB) closed higher on Monday, November 22, closing at $9.17, 0.11% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Morgan Stanley raised its holdings in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 77.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 627,851 shares of the biotechnology companys stock after acquiring an additional 274,093 shares during the quarter. Morgan Stanley owned approximately 0.68% []

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have earned a consensus recommendation of Buy from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The []